[1]
2024. Establishing a Risk Model for Diabetic Nephropathy and Addressing the Therapeutic Effect of Combined Epalrestat- Dapagliflozin Regimen.
Iranian Journal of Kidney Diseases
. 18, 05 (Oct. 2024). DOI:
https://doi.org/10.52547/ax1vqh41
.